BRIDGEWATER, N.J., Feb. 8, 2024
/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global
biopharmaceutical company on a mission to transform the lives of
patients with serious and rare diseases, today announced that it
will release its fourth-quarter and full year 2023 financial
results on Thursday, February 22,
2024.
Insmed management will host a conference call for investors
beginning at 8:30 a.m. ET on Thursday,
February 22, 2024, to discuss the financial results and
provide a business update.
Shareholders and other interested parties may participate in the
conference call by dialing (888) 210-2654 (U.S. and international)
and referencing access code 7862189. The call will also be webcast
live on the company's website at www.insmed.com.
A replay of the conference call will be accessible approximately
1 hour after its completion through March
23, 2024, by dialing (800) 770-2030 (U.S. and international)
and referencing access code 7862189. A webcast of the call will
also be archived for 90 days under the Investor Relations section
of the company's website at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is a first-in-disease
therapy approved in the United
States, Europe, and
Japan to treat a chronic,
debilitating lung disease. The Company is progressing a robust
pipeline of investigational therapies targeting areas of serious
unmet need, including neutrophil-mediated inflammatory diseases and
rare pulmonary disorders. Insmed is also advancing an early-stage
research engine encompassing a wide range of technologies and
modalities, including artificial intelligence-driven protein
engineering, gene therapy, and protein manufacturing. Insmed is
headquartered in Bridgewater, New
Jersey, with additional offices and research locations
throughout the United States,
Europe, and Japan. Visit www.insmed.com to learn more.
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-fourth-quarter-and-full-year-2023-financial-results-conference-call-on-thursday-february-22-2024-302057028.html
SOURCE Insmed Incorporated